AMARIN CORP PLC -ADR (AMRN)
US0231112063 - ADR
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action...
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
/CNW/ - HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric...
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published...
Why Amarin Stock Was Rocketing Higher on Wednesday
There was unambigously good news about the company's single commercialized medication.
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
Company’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
Company’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039...
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
-- Subgroup Analyses from REDUCE-IT® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting -- DUBLIN,...
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript
AMRN earnings call for the period ending December 31, 2023.
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-- Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 ---- Reaffirms Year-End 2023 Cash Position...
Amarin Q4 2023 Earnings Preview (NASDAQ:AMRN)
Amarin is set to announce its Q4 earnings results, with an EPS estimate of -$0.03 and a revenue estimate of $71.1M.
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a...
HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan
/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric...
Amarin Chairman & CEO Issue Letter to Shareholders
Amarin Chairman & CEO Issue Letter to Shareholders
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Chairman...
First Week of March 15th Options Trading For Amarin (AMRN)
Why Amarin Stock Skyrocketed Today
The biopharma company announced a big repurchase plan, along with strong preliminary Q4 results.
Amarin shares surge on higher-than-expected preliminary Q4 results (NASDAQ:AMRN)
Amarin (AMRN) reports higher than expected Q4 revenues, exceeding analysts' estimates.
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Sarissa Capital says Amarin stock undervalued (NASDAQ:AMRN)
Sarissa Capital Management on Monday said that it believed Amarin's (AMRN) stock was "significantly undervalued." Read more here.
JP Morgan bullish on six Big Biotechs, rates nine others neutral or lower (NASDAQ:INSM)
JP Morgan said it was bullish on Insmed (INSM), Denali (DNLI), Immunocore (IMCR), Crinetics (CRNX), Mirum (MIRM) and BioCryst (BCRX), rating all as overweight. Read more here.